Experiences with

Ropeginterferon alfa-2b

Discussion; The results in our study demonstrate that the new dosing regimen of 250-350-500 µg of ropeginterferon alfa-2b is well-tolerated and highly efficacious in patients suffering from PV.

No specific baseline characteristics among low-risk PV patients appear to be associated with long-term response to ropeginterferon alfa-2b.

 « The National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®) have recently been updated to include ropeginterferon alfa-2b-njft, marketed as BESREMi®, as a preferred first-line cytoreductive therapy option for the treatment of adults with symptomatic, low-risk

This potential advantage should be considered when evaluating the individual risk-benefit relationship for ropeginterferon alfa-2b treatment in patients with PV » https://www.nature.com/articles/s41375-023-02008-6

Over a lifetime, the model showed that patients who received ropeginterferon alfa-2b-njft had more years alive (0.4), and higher QALYs (0.4), and higher cost (141,783). What do the results mean?

It is to determine the efficacy of using Ropeginterferon alfa-2b-njft for the treatment of Essential Thrombocythemia. It has been approved for use in the treatment of PV, but not ET in the US, as I understand it.

For the last 60 years I have been a vigilant weight watcher, daily exerciser and have watched my calorie intake. When I commenced treatment for my Essential Thrombocytosis in January 2021, my weight was 53.5kg. Three years later this has ballooned to 60.3kg, despite my efforts to control any

https://www.onclive.com/view/nccn-guidelines-list-ropeginterferon-alfa-2b-as-preferred-treatment-in-polycythemia-vera

Hola! I'm new to this group and newly diagnosed with essential thrombocythemia. The treatment prescribed is peginterferon alfa-2a. So far I have done one treatment and wow does it suck! I haven't seen anyone else talking about this course of treatment. Is anyone else doing this? I sure could use some

My consultant has said I need to start treatment for PV and has asked me to choose between them. I'd really welcome any recommendations. I am new to this site, apologies uf this has been asked before.

https://www.businesswire.com/news/home/20230223005186/en/PharmaEssentia-Initiates-Phase-2b-Trial-of-ropeginterferon-alfa-2b-njft-for-Essential-Thrombocythemia-ET-in-North-America

https://www.businesswire.com/news/home/20230202005200/en/Clinical-Review-of-ropeginterferon-alfa-2b-Suggests-Amended-Dosing-Schedule-May-Support-Improved-Clinical-Outcomes-in-Polycythemia-Vera

alfa-2b not only reduces the number of required phlebotomies but also brings additional significant benefit to the patient by better controlling the target hematocrit, stabilizing the disease and improving patients' quality of life."

My focus is in myeloid malignancies with a research focus in myeloproliferative neoplasms.Graphic: What is ropeginterferon?Dr. Mascarenhas: So, Ropeginterferon is a type of interferon alfa-2b.

can anyone confirm whether Besremi / ropeginterferon-Alfa-2b is approved for first line treatment of Polycythemia Vera on the NHS. im 41, diagnosed 5years ago, fit and healthy but obviously concerned about the long term progression risk.

Across the studies, ropeginterferon alfa-2b was generally well-tolerated. No thromboembolic complications have been reported with the accelerated titration regimen in PV.

Third generation pegylated IFNα, ropeginterferon alfa-2b (ropegIFN; Besremi), was recommended by the European Medicine Authority (EMA) for treatment of Polycythaemia Vera (PV) following a Phase III trial (PROUD-PV / CONTINUATION-PV).

[The response outcomes observed in multiple clinical trials of ropeginterferon alfa-2b confirm clinical benefits in MPN patients. Emerging data utilizing the 250-350-500 mcg regimen suggest that a higher initial dose with faster dose titration may lead to earlier complete hematological remission.

In the FDA label it says there isn't any: "BESREMi (ropeginterferon alfa-2b-njft) injection is a sterile, preservative-free..." https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761166s000lbl.pdf -In the Euro label there is no mention of preservative at all.

There has been a recent resurgence of interest in interferons for MPNs given the development of pegylated formulations, including pegylated interferon alfa-2a (Pegasys), pegylated interferon alfa-2b (PegIntron), and ropeginterferon alfa-2b (Besremi).